Daniela Weiskopf

US Patent:

20130202634, Aug 8, 2013

Filed:

Dec 18, 2012

Appl. No.:

13/719227

Inventors:

La Jolla Institute For Allergy And Immunology - La Jolla CA, US
Lauren Yauch - La Jolla CA, US
Alessandro Sette - San Diego CA, US
Daniela Weiskopf - San Diego CA, US

Assignee:

LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY - La Jolla CA

International Classification:

C07K 7/08
C07K 7/06

US Classification:

4241861, 530326, 530328

Abstract:

Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8 T cell response or an anti-DV CD4 T cell response. Such peptides, nucleotide sequences and compositions can also be used for and in methods of vaccination/immunization of a subject against Dengue virus (DV) (e.g., to provide protection against DV infection and/or pathology), and for treatment of a subject in need thereof, for example, treatment of the subject for a Dengue virus (DV) infection or pathology.

US Patent:

20160130305, May 12, 2016

Filed:

Jul 15, 2015

Appl. No.:

14/800468

Inventors:

- La Jolla CA, US
Lauren Yauch - La Jolla CA, US
Alessandro Sette - San Diego CA, US
Daniela Weiskopf - San Diego CA, US

International Classification:

C07K 14/005
C12N 7/00
A61K 39/12

Abstract:

Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8 T cell response or an anti-DV CD4 T cell response. Such peptides, nucleotide sequences and compositions can also be used for and in methods of vaccination/immunization of a subject against Dengue virus (DV) (e.g., to provide protection against DV infection and/or pathology), and for treatment of a subject in need thereof, for example, treatment of the subject for a Dengue virus (DV) infection or pathology.